FDA PMA FDA Class 2 Approved 🇺🇸 United States

Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus

PMA: P090008 · Supplement: S006 · Decision Apr 25, 2012
Classifications
1
FEI Numbers
24
Registration Numbers
24

Basic Information

Device Name
Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus
Trade Name
ELECSYS ANTI-HCV IMMUNOASSAY
PMA Number
P090008
Supplement Number
S006
Device Class
FDA Class 2
Product Code
MZO
Generic Name
Assay, enzyme linked immunosorbent, hepatitis c virus
Medical Specialty
Unknown
Advisory Committee
Microbiology
Decision
Approved
Decision Code
APPR
Decision Date
April 25, 2012
Date Received
November 1, 2011
Supplement Type
Normal 180 Day Track
Supplement Reason
Change Design/Components/Specifications/Material
Expedited Review
N

Advisory Committee Statement

APPROVAL FOR THE EXTENSION OF THE ELECSYS ANTI-HCV IMMUNOASSAY ANDPRECICONTROL ANTI-HCV IMMUNOASSAY ONTO THE COBAS E 602 IMMUNOASSAY ANALYZER. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME ELECSYS ANTI-HCV IMMUNOASSAY AND IS INDICATED FOR: ELECSYS ANTI-HCV IMMUNOASSAY - THE ELECSYS ANTI-HCV IMMUNOASSAY IS AN IN VITRO DIAGNOSTIC TEST FOR THE QUALITATIVEDETECTION OF TOTAL ANTIBODIES TO HEPATITIS C VIRUS (ANTI-HCV) IN HUMAN SERUM OR PLASMA (POTASSIUM EDTA, LITHIUM HEPARIN AND SODIUM HEPARIN). ASSAY RESULTS, IN CONJUNCTION WITH OTHER LABORATORY RESULTS AND CLINICAL INFORMATION, MAY BE USED TO AID IN THE PRESUMPTIVE DIAGNOSIS OF HCV INFECTION IN PERSONS WITH SIGNS AND SYMPTOMS OF HEPATITIS AND IN PERSONS AT RISK FOR HEPATITIS C INFECTION. THIS TEST DOES NOT DETERMINE THE STATE OF INFECTION OR ASSOCIATED DISEASE. THE ELECTROCHEMILUMINESCENCE IMMUNOASSAY "ECLIA" IS INTENDED FOR USE ON COBAS E 601 AND COBAS E 602 IMMUNOASSAY ANALYZERS.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
MZO Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus